Graeme Clark Collection
Permanent URI for this collection
Search Results
1 - 3 of 3
-
ItemImplant designs for future coding strategies( 1995)This paper briefly describes the history of speech processing developments leading to the presently available Speak processing strategy. The similarities and differences of the Speak and Continuous Interleaved Sampling (CIS) strategies are then discussed and some recent key experimental observations are examined as a guide to potential future coding strategies. Key issues for future coding strategies and implant designs are the number of electrodes and stimulation rates in use. Consideration of these issues has led to development of a prototype implant to be used for advanced speech-processing research.
-
ItemSpeech perception in children using the advanced Speak speech-processing strategy( 1995)The Speak speech-processing strategy, developed by the University of Melbourne and commercialized by Cochlear Pty Limited for use in the new Spectra 22 speech processor, has been shown to provide improved speech perception for adults in both quiet and noisy situations. The present study evaluated the ability of children experienced in the use of the Multipeak (Mpeak) speech-processing strategy (implemented in the Nucleus Minisystem-22 cochlear implant) to adapt to and benefit from the advanced Speak speech-processing strategy (implemented in the Nucleus Spectra 22 speech processor). Twelve children were assessed using Mpeak and Speak over a period of 8 months. All of the children had over 1 year's previous experience with Mpeak, and all were able to score significantly on open-set word and sentence tests using the cochlear implant alone. Children were assessed with both live-voice and recorded speech materials, including Consonant-Nucleus-Consonant monosyllabic words and Speech Intelligibility Test sentences. Assessments were made in both quiet and in noise. Assessments were made at 3-week intervals to investigate the ability of the children to adapt to the new speech-processing strategy. For most of the children, a significant advantage was evident when using the Speak strategy as compared with Mpeak. For 4 of the children, there was no decrement in speech perception scores immediately following fitting with Speak. Eight of the children showed a small (10% to 20%) decrement in speech perception scores for between 3 and 6 weeks following the changeover to Speak. After 24 weeks' experience with Speak, 11 of the children had shown a steady increase in speech perception scores, with final Speak scores higher than for Mpeak. Only 1 child showed a significant decrement in speech perception with Speak, which did not recover to original Mpeak levels.
-
ItemLatest results and future directions in speech processing for the Nucleus multichannel cochlear prosthesis [Abstract]( 1995)The past two years has seen the introduction of the Speak speech encoding scheme for most patients using the Nucleus 22-channel cochlear prosthesis. This scheme, based on the Spectral Maxima Speech Processor (SMSP) developed at the University of Melbourne, uses a bank of 20 band-pass filters to present detailed spectral information to the intracochlear electrode array. Clinical trials of this speech processor have shown highly significant improvements over the previous Multipeak scheme in English, German, French and Japanese speaking patients. The largest improvements were evident for open-set testing in background noise, which represents a more realistic measure of everyday benefit than testing in quiet. The latest results for adults who have changed from Multipeak to Speak will be presented, along with results over time for newly-implanted patients using the Speak scheme. New research aimed at improving the speech processing in both the spectral and temporal domains will also be discussed.